经济观察报 记者 刘晓诺 实习记者 田韫莘 杨斯涵 生病吃药，再自然不过。然而，吃药这件小事，并非对所有人都那么"一目了然"。 感冒后的程海凭记忆摸出一包粉剂，冲泡开，入口极咸。原来他喝的不是感冒灵颗粒，而是方便面调料。 程海今年25岁，因一场大病自幼双目失明，仅能感知到周遭有无光亮。回想那次经历，程海仍心有余悸："还好只是调料，如果是其他药，我可能会出问 题。" 中国绝大部分药盒包装都没有盲文等无障碍措施，盲人等视障人士以及视力衰退的老年人，几乎无法直接从包装上获取药名和用法用量等关键信息。 世界卫生组织援引的一项研究估测，2020年，中国有约890万名盲人。广义的视力障碍者则更多，据中国残疾人联合会数据，中国有1732万名视障人士。 2026年1月27日，新修订的《中华人民共和国药品管理法实施条例》正式公布，其中要求："药品上市许可持有人应当按照国务院药品监督管理部门的规定， 提供语音、大字、盲文或者电子等无障碍格式版本的药品标签、说明书，方便残疾人、老年人用药。" 陕西省人民医院副主任药师郭振军记得，西安有位盲人阿姨因自卑没有出席女儿婚礼，晚上八点多家人回家发现她躺在地上，手边散落着各种药盒，但人已 因 ...

Core Viewpoint - Norfloxacin is a synthetic antibacterial compound belonging to the fluoroquinolone class, widely used in both human and veterinary medicine for its broad-spectrum antibacterial properties [1][2][3]. Market Overview - The global market for Norfloxacin is projected to reach USD 456 million in 2024, with an expected increase to USD 475 million in 2025, reflecting a compound annual growth rate (CAGR) of 4.5% over the next six years [5]. Clinical Applications - In human medicine, Norfloxacin is primarily used to treat infections caused by sensitive bacteria, particularly Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, commonly associated with urinary tract infections [2]. - It is also effective against gastrointestinal infections and can be administered orally or via injection, achieving high concentrations in urine [2]. Veterinary Applications - Norfloxacin is utilized in veterinary medicine to prevent and treat bacterial diseases in livestock, such as chicken and pig infections, by incorporating it into animal feed or drinking water [3]. Formulation Types - **Oral Formulations**: The most widely used form, including tablets and capsules, effective for treating urinary and gastrointestinal infections [4]. - **Topical Formulations**: Includes creams and gels for local infections, requiring high purity and low impurity levels [4]. - **Injectable Formulations**: Used for severe infections requiring rapid action, though this form has a smaller market share due to safety concerns [4]. Industry Chain - The upstream of the Norfloxacin industry chain consists of key starting materials and intermediates, while the midstream involves manufacturers of the active pharmaceutical ingredient (API) who must comply with stringent quality standards [6]. - The downstream includes formulation companies and distribution channels, with a significant presence in countries like China and India [6]. Industry Policies - Regulatory scrutiny on fluoroquinolone drugs has increased, with recommendations to limit their use to reduce adverse effects, impacting prescription patterns and market dynamics [7]. Development Trends - Short-term demand for Norfloxacin is driven by generic drug needs and regional epidemiology, while long-term strategies focus on quality compliance and cost reduction through process optimization [8]. Entry Barriers - The market faces challenges such as regulatory risks, environmental compliance costs, and intense competition among numerous small manufacturers, particularly in major API supply countries [9].

Group 1: Financial Performance - The company's total revenue for 2024 was ¥708,834,125.46, with a net profit of ¥64,571,985.96 [4] - In Q1 2025, the revenue reached ¥161,979,567.81, with a net profit of ¥15,246,208.73 [4] - Export sales for 2024 amounted to ¥188,583,231.00, representing a growth of 17.88% compared to 2023 [2][4] Group 2: Market Expansion and Strategy - The company is focusing on expanding its overseas market, particularly in India, while maintaining its domestic market leadership [3][4] - Plans to enhance market share include developing new customer bases and exploring new industries through a "self + integration" collaborative development model [4][5] - The company aims to optimize its operational strategies to improve profitability, including enhancing product applications in other sectors and strengthening sales capabilities [5] Group 3: Product Development and Innovation - A new production line for Norfloxacin with an annual capacity of 1,000 tons is expected to be operational by April 30, 2025, leveraging innovative production techniques to reduce costs [3] - The company is committed to continuous R&D investment and product development, focusing on expanding its product range and improving existing products [4][6] - Collaboration with universities and research institutions is part of the strategy to accelerate innovation and sustainable development [6] Group 4: Industry Outlook - The chemical manufacturing industry saw a revenue increase of 4.2% in 2024, with total revenue reaching ¥91,986.4 billion [6] - The pharmaceutical manufacturing sector is expected to grow due to rising global population and aging demographics, leading to increased drug demand [6] - The agrochemical industry is entering a new phase characterized by high-quality and green development, with demand growth in the Asia-Pacific and Latin America regions [6]